PMID- 29475959
OWN - NLM
STAT- MEDLINE
DCOM- 20190521
LR  - 20240207
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 131
IP  - 18
DP  - 2018 May 3
TI  - High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with 
      diffuse large B-cell lymphoma morphology.
PG  - 2060-2064
LID - 10.1182/blood-2017-12-820605 [doi]
AB  - High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements 
      (HGBL-DH/TH) is a newly defined entity in the latest World Health Organization 
      Classification. Accurate diagnosis would appear to mandate fluorescence in situ 
      hybridization (FISH) for all tumors with diffuse large B-cell lymphoma (DLBCL) 
      morphology. We present the results of FISH, cell-of-origin, and 
      immunohistochemistry (IHC) testing from 1228 DLBCL biopsies from 3 clinical 
      trials and a population-based registry. HGBL-DH/TH made up 7.9% of the DLBCL, 
      confined primarily to the germinal center B-cell-like (GCB; 13.3%) compared with 
      activated B-cell-like (ABC; 1.7%) subtype (P < .001). HGBL-DH/TH with BCL2 
      rearrangement is a GCB phenomenon with no cases observed in 415 ABC DLBCL. A 
      screening strategy restricting FISH testing to tumors of GCB subtype (by Lymph2Cx 
      or Hans IHC) plus dual protein expression of MYC and BCL2 by IHC could limit 
      testing to 11% to 14% of tumors, with a positive predictive value of 30% to 37%; 
      however, this strategy would miss approximately one-quarter of tumors with 
      HBGL-DH/TH with BCL2 rearrangement and one-third of all HGBL-DH/TH. These results 
      provide accurate estimation of the proportion of HGBL-DH/TH among tumors with 
      DLBCL morphology and allow determination of the impact of various methods 
      available to screen DLBCL tumors for FISH testing.
CI  - (c) 2018 by The American Society of Hematology.
FAU - Scott, David W
AU  - Scott DW
AD  - Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, Canada.
AD  - Department of Medicine, University of British Columbia, Vancouver, Canada.
FAU - King, Rebecca L
AU  - King RL
AD  - Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
FAU - Staiger, Annette M
AU  - Staiger AM
AD  - Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany.
AD  - Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart and 
      University of Tuebingen, Tuebingen, Germany.
FAU - Ben-Neriah, Susana
AU  - Ben-Neriah S
AD  - Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, Canada.
FAU - Jiang, Aixiang
AU  - Jiang A
AD  - Department of Molecular Biology and Biochemistry, Simon Fraser University, 
      Vancouver, Canada.
FAU - Horn, Heike
AU  - Horn H
AD  - Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart and 
      University of Tuebingen, Tuebingen, Germany.
FAU - Mottok, Anja
AU  - Mottok A
AD  - Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, Canada.
AD  - Institute of Pathology, Wurzburg University and Comprehensive Cancer Center 
      Mainfranken, Wurzburg, Germany.
FAU - Farinha, Pedro
AU  - Farinha P
AD  - Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, Canada.
FAU - Slack, Graham W
AU  - Slack GW
AD  - Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, Canada.
FAU - Ennishi, Daisuke
AU  - Ennishi D
AD  - Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, Canada.
FAU - Schmitz, Norbert
AU  - Schmitz N
AD  - Department of Medicine, Hematology and Oncology, University Hospital Muenster, 
      Muenster, Germany.
FAU - Pfreundschuh, Michael
AU  - Pfreundschuh M
AD  - Department of Medicine, Hematology and Oncology, University Hospital Muenster, 
      Muenster, Germany.
FAU - Nowakowski, Grzegorz S
AU  - Nowakowski GS
AD  - Department of Internal Medicine I, Saarland University Medical School, 
      Homburg/Saar, Germany.
FAU - Kahl, Brad S
AU  - Kahl BS
AD  - Department of Oncology, Mayo Clinic, Rochester, MN; and.
FAU - Connors, Joseph M
AU  - Connors JM
AD  - Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, Canada.
AD  - Department of Medicine, University of British Columbia, Vancouver, Canada.
FAU - Gascoyne, Randy D
AU  - Gascoyne RD
AD  - Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, Canada.
FAU - Ott, German
AU  - Ott G
AD  - Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany.
FAU - Macon, William R
AU  - Macon WR
AD  - Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
FAU - Rosenwald, Andreas
AU  - Rosenwald A
AD  - Institute of Pathology, Wurzburg University and Comprehensive Cancer Center 
      Mainfranken, Wurzburg, Germany.
LA  - eng
GR  - U24 CA196172/CA/NCI NIH HHS/United States
GR  - U10 CA180790/CA/NCI NIH HHS/United States
GR  - U10 CA180794/CA/NCI NIH HHS/United States
GR  - U10 CA180799/CA/NCI NIH HHS/United States
GR  - U10 CA180820/CA/NCI NIH HHS/United States
GR  - U10 CA180833/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20180223
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (Proto-Oncogene Proteins c-bcl-6)
RN  - 0 (Proto-Oncogene Proteins c-myc)
SB  - IM
CIN - Blood. 2018 May 3;131(18):1997-1998. PMID: 29724715
MH  - Cell Line, Tumor
MH  - *Gene Rearrangement
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphoma, Large B-Cell, Diffuse/*diagnosis/drug therapy/*genetics
MH  - Neoplasm Grading
MH  - Proto-Oncogene Proteins c-bcl-2/*genetics
MH  - Proto-Oncogene Proteins c-bcl-6/*genetics
MH  - Proto-Oncogene Proteins c-myc/*genetics
PMC - PMC6158813
COIS- Conflict-of-interest disclosure: D.W.S has performed consultancy for Janssen and 
      Celgene. B.S.K. has performed consulting for, and received research funding from, 
      Genentech and Celgene. D.W.S., J.M.C., R.D.G., G.O., and A.R. are named inventors 
      on a patent that has been licensed to NanoString Technologies. The remaining 
      authors declare no competing financial interests.
EDAT- 2018/02/25 06:00
MHDA- 2019/05/22 06:00
PMCR- 2019/05/03
CRDT- 2018/02/25 06:00
PHST- 2017/12/20 00:00 [received]
PHST- 2018/02/13 00:00 [accepted]
PHST- 2018/02/25 06:00 [pubmed]
PHST- 2019/05/22 06:00 [medline]
PHST- 2018/02/25 06:00 [entrez]
PHST- 2019/05/03 00:00 [pmc-release]
AID - S0006-4971(20)32263-1 [pii]
AID - 2017/820605 [pii]
AID - 10.1182/blood-2017-12-820605 [doi]
PST - ppublish
SO  - Blood. 2018 May 3;131(18):2060-2064. doi: 10.1182/blood-2017-12-820605. Epub 2018 
      Feb 23.